Voya Investment Management LLC lessened its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 9.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,077,091 shares of the company’s stock after selling 113,701 shares during the quarter. Eli Lilly and Company makes up approximately 1.1% of Voya Investment Management LLC’s investment portfolio, making the stock its 12th largest position. Voya Investment Management LLC owned 0.11% of Eli Lilly and Company worth $1,245,481,000 at the end of the most recent quarter.
Other hedge funds have also added to or reduced their stakes in the company. Coastal Bridge Advisors LLC acquired a new position in Eli Lilly and Company during the 2nd quarter worth about $2,959,000. Birinyi Associates Inc. grew its position in shares of Eli Lilly and Company by 32.6% in the 3rd quarter. Birinyi Associates Inc. now owns 1,460 shares of the company’s stock valued at $1,689,000 after buying an additional 359 shares during the last quarter. Bernicke Wealth Management Ltd. bought a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at about $5,001,000. Mosaic Family Wealth Partners LLC increased its stake in shares of Eli Lilly and Company by 70.6% in the second quarter. Mosaic Family Wealth Partners LLC now owns 3,455 shares of the company’s stock valued at $4,144,000 after buying an additional 1,430 shares during the period. Finally, Trillium Asset Management LLC increased its stake in shares of Eli Lilly and Company by 1,302.8% in the third quarter. Trillium Asset Management LLC now owns 5,036 shares of the company’s stock valued at $5,831,000 after buying an additional 4,677 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.
Eli Lilly and Company Stock Performance
LLY stock opened at $1,412.63 on Wednesday. The stock has a 50-day moving average price of $1,253.71 and a 200-day moving average price of $1,114.28. Eli Lilly and Company has a 1-year low of $850.51 and a 1-year high of $1,475.25. The company has a current ratio of 1.39, a quick ratio of 1.00 and a debt-to-equity ratio of 1.17. The firm has a market cap of $1.33 trillion, a PE ratio of 45.85, a price-to-earnings-growth ratio of 1.71 and a beta of 0.40.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its earnings results on Thursday, October 29th. The company reported $7.48 EPS for the quarter, beating the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The company had revenue of $24.40 billion for the quarter, compared to analyst estimates of $22.58 billion. During the same quarter in the prior year, the company earned $7.02 EPS. The firm’s revenue for the quarter was up 38.6% compared to the same quarter last year. As a group, equities research analysts expect that Eli Lilly and Company will post 35.70 earnings per share for the current year.
Eli Lilly and Company Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, November 13th. This represents a $6.92 annualized dividend and a yield of 0.5%. Eli Lilly and Company’s payout ratio is 22.46%.
Insider Transactions at Eli Lilly and Company
In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the transaction, the executive vice president directly owned 4,137 shares in the company, valued at approximately $5,802,225.24. This represents a 54.72% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.14% of the company’s stock.
Latest Eli Lilly and Company News
Investors following LLY have been watching these news items:
- Positive Sentiment: New ObesityWeek 2026 results for Lilly’s obesity and cardiometabolic portfolio—including retatrutide, EloraTZP and Foundayo—showed benefits across weight loss and related conditions such as blood-sugar control, sleep apnea and knee osteoarthritis. The breadth of findings supports Lilly’s effort to build a broader cardiometabolic franchise. Article: Positive Trial Results Could Be A Big Moment For Eli Lilly Stock
- Neutral Sentiment: Lilly agreed to acquire Calytrix Bio for up to $1.5 billion to add experimental treatments for rare blood cancers. The acquisition broadens its oncology pipeline, but clinical and regulatory milestones will determine the ultimate value and cost. Article: Eli Lilly to Acquire Calytrix Bio for Up to $1.5 Billion to Expand Blood Cancer Portfolio
- Negative Sentiment: An extortion group claims it has patient and prescriber data linked to a third-party vendor serving Lilly. Lilly reportedly found no unauthorized access to its own systems, but a confirmed exposure could create privacy, regulatory and reputational concerns. Article: Eli Lilly Caught in Vendor Hack as Extortion Group Threatens to Leak Data on 1.2 Million Patients
Analysts Set New Price Targets
LLY has been the subject of a number of analyst reports. Citigroup raised their price objective on Eli Lilly and Company from $1,600.00 to $1,650.00 and gave the stock a “buy” rating in a research report on Friday, October 30th. Sanford C. Bernstein reiterated an “outperform” rating and issued a $1,450.00 target price on shares of Eli Lilly and Company in a report on Monday, October 26th. UBS Group increased their target price on shares of Eli Lilly and Company from $1,425.00 to $1,625.00 and gave the company a “buy” rating in a research report on Friday, October 30th. Scotiabank raised their price target on shares of Eli Lilly and Company from $1,300.00 to $1,605.00 and gave the stock a “sector outperform” rating in a report on Friday, October 30th. Finally, Wells Fargo & Company boosted their price target on shares of Eli Lilly and Company from $1,330.00 to $1,500.00 and gave the stock an “overweight” rating in a research report on Friday, October 30th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $1,422.00.
Get Our Latest Stock Analysis on LLY
Eli Lilly and Company Company Profile
Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.
Further Reading
- Five stocks we like better than Eli Lilly and Company
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
